GW-2016 Hot Sale Lapatinib CAS 231277-92-2

Basic Info

Model No.: CAS 231277-92-2

Certification: GMP

Additional Info

Packaging: 10g 100g 1kg

Productivity: 10000

Brand: chenyi

Transportation: Ocean,Land,Air

Place of Origin: China

Supply Ability: 10

Certificate: Enterprise standard

HS Code: 2934999090

Port: QINGDAO,JINAN

Product Description

Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. Check for active clinical trials or closed clinical trials using this agent.

Properties:
Appearance & Physical State: Powder
Density: 1.381 g/cm3
Boiling Point: 750.7ºC at 760 mmHg
Flash Point: 407.8ºC
Refractive Index: 1.645
Vapor Pressure: 0mmHg at 25°C

Fuction

Lapatinib is used in combination with capecitabine for the treatment of erbb-2 overexpression, and has previously been treated

with anthracycline, taxol, and trastuzumab (herceptin) for advanced or metastatic breast cancer.Lapatinib, an anti-cancer drug

developed and manufactured by glaxosmithkline, was approved by the us food and drug administration on March 13, 2007.The currently

approved indication is the combination with Capecitabine for advanced or metastatic breast cancer, which must be treated with

other first-line drugs and fails.Its U.S. product name is Tykerb, while in Europe it will be Tyverb once approved by the European

governing body.Lapatinib is unique in that patients who have been treated with other chemotherapy drugs do not develop

cross-resistance to it and can effectively slow the progression of breast cancer.There are many other clinical trials underway to

study the effects of lapatinib on other cancers.